
# Lebrikizumab▼: Short and Long-Term Disease Control in Moderate-to-Severe AD Through Selective IL-13 Inhibition


Citation: EMJ. 2024;9[3]:46-47. https://doi.org/10.33590/emj/BUHL9841.


## IL-13 is the key cytokine in the skin of patients with AD<sup>1</sup>



### **Mechanism of Action** of Lebrikizumab

Lebrikizumab selectively targets IL-13 and inhibits its signalling<sup>3,5,6</sup>







IL-13Rα2 IL-13 regulation: Decov receptor Skin structural cells


## Key Lebrikizumab Data: Monotherapy ADvocate 1 and ADvocate 2 trials<sup>8,9</sup>

Short-term efficacy from ADvocate 1 and ADvocate 2 trials: >50% patients achieved EASI-75 at Week 16



EASI-75 with Q4W monotherapy between Weeks 16 and 52





The most common adverse reactions are conjunctivitis (6.9%), injection site reactions (2.6%), conjunctivitis allergic (1.8%), and dry eye (1.4%). The safety profile of lebrikizumab as monotherapy through Week 52 or in combination with TCS through Week 56 is consistent with the safety profile observed up to Week 16.

#### Abbreviations

AD: atopic dermatitis: CD4: cluster of differentiation 4: EASI: Eczema Area and Severity Index: II-13: interleukin-13: II-13Ra: interleukin-13 receptor subunit alpha: II 4Ra: interleukin-4 receptor alpha: IGA: Investigator Global Assessment: ITT: interleukin-to-treat JAK: Janus kinase; LEB: lebrikizumab; mMPP: modified maintenance primary population; mITT: modified intention-to-treat; Q2W: every 2 weeks; Q4W: every 4 weeks; Ra: receptor a; SCORAD: SCORing Atopic Dermatitis; TCS: topical corticosteroids.

- Tsoi LC et al. Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneit compared to psoriasis. J Invest Dermatol. 2019;139(7):1480-9.
- 2. La Grutta S et al. CD4(+)IL-13(+) cells in peripheral blood well correlates with the severity of atopi
- dermatitis in children. Allergy. 2005;60(3):391-5. Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy
- 2020.75(1).54-62 4. Napolitano M et al. The hidden sentinel of the skin: an overview on the role of interleukin-13 in atopic
- . rmatitis. Front Med. 2023;10:1165098.
- 5. Movie M et al. Understanding the immune landscape in atopic dermatitis: the era of biologics and emerging therapeutic approaches. Exp Dermatol. 2019;28(7):756-68.
- 6. Lytvyn Y, Gooderham M. Targeting interleukin 13 for the treatment of atopic dermatitis
- naceutics. 2023;15(2):568. Okragly AJ et al. Binding, neutralization and internalization of the Interleukin-13 antibody, lebrikizumab. Dermatol Ther (Heidelb). 2023;13(7):1535-47.
- 8. Silverberg JI et al. ADvocate 1 and ADvocate 2 Investigators. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080-91.
- Blauvelt A et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol 2023-188(6)-740-8
- 10. European Medicines Agency (EMA), Lebrikizumab summary of product characteristics, Available at: https://www.ema.europa.eu/en n/documents/product-information/ebglyss-epar-product-information en.pdf. Last accessed: 9 April 2024.

UK-Adverse event should be reported. Reporting form and information can be found at MHRA https://vellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple Store, Adverse events should also be reported to Almirall Ltd. Tel. 0800 0087 399

UK Prescribing Information can be found here

### Lebrikizumab:

- downstream signalling
- symptoms of moderate to severe AD
- Is administered every 4 weeks as maintenance therapy •



The publication of this infographic was funded by **Committee** 

IL-13 drives several key signs and symptoms of atopic dermatitis<sup>3,4</sup>

#### Selectively binds IL-13 with high affinity and inhibits its

Has demonstrated short- and long-term efficacy in signs and Shows a consistent safety profile in short- and long-term use<sup>7</sup>



UK-EBG-2400049 | August 2024